Extended Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomLina liseniorJohn leonardKallikrein reductionasTimothyj craigEuropean academy of allergyBiomedical sciences at penn state universityIntellia therapeutics incExchange commissionCorporate communicationsExtended phaseEuropean academyClinical immunologyHybrid congressIntellia presidentChief executive officer

Intellia Therapeutics Announces New Positive Clinical Data

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients.

United kingdomIan karpJohn leonardAlina liTimothyj craigMatt crensonExchange commissionCorporate communicationsIntellia therapeutics incBiomedical sciences at penn state universityEuropean academy of allergyClinical programExtended phaseEuropean academyClinical immunologyHybrid congress